This posit is coming to reality with the 2022 FDA approval of Enhertu (fam‐trastuzumab‐deruxtecan‐nxki), the first treatment for unresectable or metastatic HER2‐low breast cancer.14 This evidence concerns the gene ERBB2 and breast cancer.